Clonal hematopoiesis (CH) has been recognized as a predisposing factor for the development of myeloid malignancies. Its detection has been reported at different frequencies across studies, based on the type of genome scanning approach used and the population studied, but the latest insights recognize its virtual ubiquitous presence in older individuals. The discovery of CH in recent years paved the way for a shift in the paradigm of our understanding of the biology of therapy-related myeloid malignancies (t-MNs). Indeed, we moved from the concept of a treatment-induced lesion to a model where CH precedes the commencement of any cancer-related treatment in patients who subsequently develop a t-MN. Invariant patterns of genes seem to contribute to the arising of t-MN cases, with differences regarding the type of treatment received. Here, we review the principal studies concerning CH, the relationship with myeloid progression and the mechanisms of secondary t-MN development.

Gurnari, C., Fabiani, E., Falconi, G., Travaglini, S., Ottone, T., Cristiano, A., et al. (2021). From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. BIOLOGY, 10(2), 1-14 [10.3390/biology10020128].

From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression

Gurnari, Carmelo;Ottone, Tiziana;Voso, Maria Teresa
2021-02-06

Abstract

Clonal hematopoiesis (CH) has been recognized as a predisposing factor for the development of myeloid malignancies. Its detection has been reported at different frequencies across studies, based on the type of genome scanning approach used and the population studied, but the latest insights recognize its virtual ubiquitous presence in older individuals. The discovery of CH in recent years paved the way for a shift in the paradigm of our understanding of the biology of therapy-related myeloid malignancies (t-MNs). Indeed, we moved from the concept of a treatment-induced lesion to a model where CH precedes the commencement of any cancer-related treatment in patients who subsequently develop a t-MN. Invariant patterns of genes seem to contribute to the arising of t-MN cases, with differences regarding the type of treatment received. Here, we review the principal studies concerning CH, the relationship with myeloid progression and the mechanisms of secondary t-MN development.
6-feb-2021
In corso di stampa
Rilevanza internazionale
Editoriale
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
clonal hematopoiesis
myeloid progression
therapy-related myeloid neoplasms
Gurnari, C., Fabiani, E., Falconi, G., Travaglini, S., Ottone, T., Cristiano, A., et al. (2021). From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. BIOLOGY, 10(2), 1-14 [10.3390/biology10020128].
Gurnari, C; Fabiani, E; Falconi, G; Travaglini, S; Ottone, T; Cristiano, A; Voso, Mt
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
biology-10-00128-v2.pdf

accesso aperto

Licenza: Creative commons
Dimensione 988.06 kB
Formato Adobe PDF
988.06 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/266786
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact